Luan G Prado,Laura E Nagy
Luan G Prado
This review aims to summarize recent research using animal models, cell models, and human data regarding the role of complement in liver disease. Complement is part of the innate immune system and was initially characterized for its role in...
LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology [0.03%]
肝脏病理生物学中的长链非编码RNA、RNA治疗和新兴技术
Abid A Anwar,Nidhi Jalan-Sakrikar,Robert C Huebert
Abid A Anwar
The field of ribonucleic acid (RNA) biology has revealed an array of noncoding RNA species, particularly long noncoding RNAs (lncRNAs), which play crucial roles in liver disease pathogenesis. This review explores the diverse functions of ln...
David Hudson,Francisco Javier Valentin Cortez,Ivonne Hurtado Díaz de León et al.
David Hudson et al.
There continues to be an ongoing need for fair and equitable organ allocation. The Model for End-Stage Liver Disease (MELD) score has evolved as a calculated framework to evaluate and allocate patients for liver transplantation objectively....
Zoe Mariño,Michael L Schilsky
Zoe Mariño
The Wilson disease (WD) research field is rapidly evolving, and new diagnostic and therapeutical approaches are expected to be change-gamers in the disease for the incoming years, after decades of slow changing options. Non-ceruloplasmin-bo...
Enrico Pompili,Giulia Iannone,Daniele Carrello et al.
Enrico Pompili et al.
Acute-on-chronic liver failure (ACLF) is defined as a clinical syndrome that develops in patients with chronic liver disease characterized by the presence of organ failure and high short-term mortality, although there is still no worldwide ...
Lung-Yi Mak,Tobias Boettler,Upkar S Gill
Lung-Yi Mak
Over 300 million individuals worldwide are chronically infected with hepatitis B virus and at risk for progressive liver disease. Due to the lack of a therapy that reliably achieves viral elimination and the variability of liver disease pro...
Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury [0.03%]
营养补充剂防治药物性肝损伤的潜在价值
Namya Sethi,Manoj Khokhar,Mitali Mathur et al.
Namya Sethi et al.
Drug-induced liver injury (DILI) continues to be a major concern in clinical practice, thus necessitating a need for novel therapeutic approaches to alleviate its impact on hepatic function. This review investigates the therapeutic potentia...
Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease [0.03%]
肠道微生物组在代谢功能异常性脂肪肝病中的作用
Salim Maher,Jayashi Rajapakse,Emad El-Omar et al.
Salim Maher et al.
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-previously described as nonalcoholic fatty liver disease-continues to rise globally. Despite this, therapeutic measures for MASLD remain limited. Recently, t...
Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease [0.03%]
与代谢紊乱相关肝脂肪变性疾病的患者报告结果
Aurora Barberá,Trenton M White,Anish K Arora et al.
Aurora Barberá et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and can progress to serious complications, including metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, end...
Babu Lal Meena,Shiv Kumar Sarin
Babu Lal Meena
Portal vein thrombosis (PVT) is one of the common complications of cirrhosis. The incidence of PVT correlates with liver disease severity-higher incidence in patients with Child-Turcotte-Pugh (CTP) C, large spontaneous portosystemic shunts,...